Products Categories
| CAS No.: | 151319-34-5 |
|---|---|
| Name: | Zaleplon |
| Article Data: | 13 |
| Molecular Structure: | |
|
|
|
| Formula: | C17H15N5O |
| Molecular Weight: | 305.339 |
| Synonyms: | CL 284846;L 846;LJC 10846;N-[3-(3-Cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide;Sonata;Acetamide,N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-; |
| EINECS: | 200-659-6 |
| Density: | 1.25 g/cm3 |
| Melting Point: | 186-187 °C |
| Flash Point: | 9℃ |
| Appearance: | off-white powder |
| Hazard Symbols: |
 Xi
|
| Risk Codes: | 36/37/38 |
| Safety: | 26-36 |
| PSA: | 74.29000 |
| LogP: | 2.64078 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 173606-50-3BOC-10-AMINODECANOIC ACID
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 211914-50-0N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-(2-pyridinyl)-beta-alanine ethyl ester hydrochloride
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
Chemistry
The Molecular Structure of Zaleplon (CAS NO.151319-34-5):
Empirical Formula: C17H15N5O
Molecular Weight: 305.3339
IUPAC Name: N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
Appearance: Off-White Powder
Nominal Mass: 305 Da
Average Mass: 305.3339 Da
Monoisotopic Mass: 305.12766 Da
Index of Refraction: 1.655
Molar Refractivity: 89.66 cm3
Molar Volume: 244 cm3
Surface Tension: 50.9 dyne/cm
Density: 1.25 g/cm3
InChI
InChI=1/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
Smiles
n12c(c3cc(N(C(C)=O)CC)ccc3)ccnc1c(C#N)cn2
Synonyms: N-[3-(3-cyano-pyrazolo[1,5-a]pyrimidin-7-yl)-phenyl]-n-ethyl-acetamide ; Sonata ; N-[3-(3-cyanopyrazolo[1,5-a]py;zaleplon and intermediates ; N-[3-(3-cyanopyrazolo-[1,5-a]pyrimidin-7-yl)phenyl)-n-ethylacetamide
Product Categories: Active Pharmaceutical Ingredients;Zaleplon;Intermediates & Fine Chemicals;Pharmaceuticals
Uses
Zaleplon (CAS NO.151319-34-5) is mainly used for insomnia where difficulty in falling asleep is the primary complaint.Unlike many other hypnotic drugs, it does not interfere with sleep architecture and can be administered for up to 5 weeks without the risk of dependence or rebound insomnia upon discontinuation. Zaleplon (CAS NO.151319-34-5) has advantages over benzodiazepines in that it does not disrupt sleep architecture unlike benzodiazepines which whilst inducing sleep actually worsen the quality of it.
Safety Profile
Hazard Codes: 
Xi
Risk Statements: 36/37/38
R36/37/38: Irritating to eyes, respiratory system and skin
Safety Statements: 26-36
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice
S36: Wear suitable protective clothing
Specification
There are also some side effects which are similar to the side effects of benzodiazepines.:
Zaleplon (CAS NO.151319-34-5) is habit-forming, meaning addiction or drug dependence may occur. Stopping this medication suddenly after prolonged or frequent use may cause withdrawal effects such as mood changes, restlessness,anxietyor rebound insomnia. Zaleplon (CAS NO.151319-34-5) may cause hallucinations,severe confusion,abnormal behavior, day-time drowsiness, dizziness or lightheadedness, unsteadiness and/or falls, double vision or other vision problems, agitation, vomiting, headache, nausea, muscle weakness,diarrhea or abdominal pain, tremor, depression, vivid or abnormal dreams and memory difficulties or amnesia. However, Zaleplon (CAS NO.151319-34-5) is safer than other nonbenzodiazepine Z drugs with evidence suggesting that tolerance and rebound effects do not occur or if they do are much less frequent than with other drugs in its class.